4 OCTOBER 2018
HALL 1 HALL 2
13:00 – 17:00  SUPPORTIVE AND PALLIATIVE TREATMENTS COURSE 13:00 – 17:30  THORACIC ONCOLOGIC RADIOLOGY COURSE
13:00-13:20 Palliative care overview 13.00-13.30 Approaches and changes in solid nodule assessment (Fleishner and the reality of our country)
13:20-13:35 Approaches towards symptoms (coughing, dyspnea) 13.30-14.00 Subsolid nodules: Observation or operation?
13:35-13:50 Approaches towards symptoms (hemoptysis)
13:50-14:10 Pain mangemenet in lung cancer 14.00-14.30 Radiological findings of invasion in lung cancer
14:10-14:30 Anorexia, cachexia and nutritional support
14:30-15:00 Radiological assessment in post-operative follow-up 14:30-15:00 Radiological assessment in post-operative follow-up
14:50-15:10 Intensive care support, to whom and when?
15:00-15:30 COFFEE BREAK
15:30-15:50 Psycho-oncological support 15.30-16.00 Radiological follow-up after immunotherapy
15:50-16:10 Palliative radiotherapy 16.00-16.30 Radiological follow-up after conventional radiotherapy and SBRT
16:10-16:30 Palliative surgical interventions 16.30-17.00 Radiomics and non-CT imaging methods in lung cancers
5 OCTOBER 2018
 HALL 1  HALL 2
08:30 – 09:00 OPENING  
09:00 – 09:30 1st SESSION
Conference: Towards the 9th edition of TNM staging system: the mechanisms of revision of TNM staging system in UICC and AJCC
Hisao Asamura
09:30 – 10:40 2nd SESSION NEW STAGING AND ITS REFLECTIONS
09:30-09:45 What has the new staging system brought to the clinical practice?
09:45-10:00 PET/CT, staging and prognostic indications
10:00-10:15 Endoscopic staging (Bronchoscopy and EBUS): Its place in T and N
10:15-10:30 What has changed in lung cancer during  the last year? Role of the pathologist in staging?
10:40 – 11:00 COFFEE BREAK
11:00 – 11:45 SATELLITE SYMPOSIUM
11:45 – 13:00 LUNCH
13:00-14:15 3rd SESSION EPIDEMIOLOGY, SCREENING AND TOBACCO CONTROL  13:00-14:30 EARLY STAGE NSCLC
13:00-13:30 Screening and international applications in lung cancer .
James Jett
13:30-13:50 Recurrence patterns
 13:30-13:50  Lung cancer epidemiology in Turkey and regional factors  13:50-14:10  Neoadjuvant-adjuvant therapy, for which patients?
 13:50-14:10  Tobacco control and e-cigarette  14:10-14:30 SBRT
 14:15 – 15:00  SATELLITE SYMPOSIUM    Selected Oral Presentations
 14:30-15:00 4th SESSION CONFERENCE
14:30-15:00 Advancing the surgical management of early stage lung cancer
Bill Putnam
15:00 – 15:20 COFFEE BREAK
15:20-16:45 5th SESSION CONTROVERSIAL ISSUES and INNOVATIONS in NSCLC  
15:20-15:40 Adenocarcinoma, WHO classification and its effects on clinical application?
15:40-16:00 Mediastinal staging and surgery: Dissection or sampling?
16:00-16:20 Molecular tests – NGS (Genetic Profiling), liquid biopsy
16:20-16:40 Innovations and current status in respiratory tract cytology
16:45 – 18:00 6th SESSION PLEURAL MESOTHELIOMA WITH CASES
16:45-16:55 1st Case – Surgery
16:55-17:05 2nd Case – HIPEC
17:05-17:15 3rd Case – Pathology
17:15-17:25 4th Case – Radiation Oncology
17:25-17:35 5th CASE – Medical Oncology
 PREMIERE NIGHT
6 OCTOBER 2018
 HALL 1  HALL 2
08:30-09:40 7th SESSION IMMUNOTHERAPY  
08:30-08:45 Role of pathologist in lung cancer and immunotherapy
08:45-09:00 Role of immunotherapy in 1st and 2nd line step treatment of NSCLC 09:00-09:40 8th SESSION
09:00-09:15 Who shouldn’t receive immunotherapy? 09:00-09:30  Lessons learned from the biggest minimally invasive thoracic program in Europe                                                                              Henrik Hansen
09:15-09:30 Immunotherapy-related side effects and their management 09:30-09:40 Discussion
09:40 – 10:00 COFFEE BREAK
10:00-11:20 9th SESSION PULMONARY NODULE AND GGO  
10:00-10:20 Manegement of undefined pulmonary nodules                           James Jett
10:20-10:40 Criteria for GGO lesions to be radiologically invasive
10:40-11:00 Approach to multiple GGO (Assessment and follow-up)
11:00-11:20 Limited versus standart resection for lung cancer: JCOG sublobar resection trials and its strategy                                                             Hisao Asamura
11:20 – 12:05 SATELLITE SYMPOSIUM  11:20-12:20 10th SESSION CARCINOID TUMORS
 
11:20-11:40 Is endobronchial therapy appropriate?
11:40-12:00 Role of nuclear medicine in determination of staging and treatment
12:00-12:20 Parenchyma preserving or maximal oncologic surgery? – Is lymph node dissection necessary?
12:20 – 13:00 LUNCH
13:00-14:30 11th SESSION LOCALLY ADVANCED DISEASE  
13:00-13:20 Neoadjuvant systemic therapy
13:20-13:40 Concurrent chemoradiotherapy
13:40-14:05 Surgical treatment strategy for N2 disease – North American perspective                                                    Bill Putnam
14:05-14:30 Surgical treatment strategy for N2 disease – European perspective                                                   Henrik Hansen
14:30 – 15:15 SATELLITE SYMPOSIUM
15:15 – 15:35 COFFEE BREAK
15:35-16:55 12th SESSION TARGETTED THERAPIES IN METASTATIC DISEASE 15:35-16:30 13th SESSION Conference INNOVATİONS IN RADİOTHERAPY
15:35-15:55 New developments in molecular pathology of lung cancer 15:35-16:00 Using immunotherapy and radiation to improve systemic control for lung cancer                                                                                James Welsh
15:55-16:15 Treatment options in EGFR-mutant patients; When is liquid biopsy necessary?
16:15-16:35 Approach to patients with ALK and ROS1 mutation 16:00-16:25  Proton therapy for lung cancer                                                    James Welsh
16:35-16:55 New treatments with new targets (BRAF, MEK, MET)
   16:30-17:50 14th SESSION THYMIC TUMORS WITH CASES
16:30-16:50 What has the new staging system brought?
16:50-17:10 Neoadjuvant therapy and response assessment
17:10-17:30 Surgical treatment, Until which limit?
17:30-17:50 The place of radiotherapy
  Selected Oral Presentations
7 OCTOBER 2018
 HALL 1  HALL 2
08:30 – 10:00 15th SESSION SMALL-CELL LUNG CANCER 08:30-10:00 16th SESSION NATIONAL RESULTS OF MULTIMODALITY TREATMENT INCLUDING SURGERY FOR N2 DISEASE (INVITED ORAL PRESENTATIONS)
08:30-08:50 Innovations in systemic treatment  
08:50-09:10 Role of immunotherapy
09:10-09:30 Role of radiotherapy in limited and extensive stages disease
09:30-09:50 Role of surgery
09:50-10:00 Selected oral presentations
10:00-11:15 Oral Presentations 10:00 – 10:45 RATIONAL DRUG

Rational drug use presentation

    10:45 – 12:00 Oral Presentations
12:00 CLOSING CEREMONY